Sign in
NeurosciencebioRxiv
Preprint

Lysine 117 on ataxin-3 modulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3

Jessica R. Blount, Nikhil C. PateliD, Kozeta Libohova, Autumn L. Harris, Wei‐Ling TsouiD, Alyson L. SujkowskiiD, Sokol V. TodiiD

Abstract

Ataxin-3 (Atxn3) is a deubiquitinase with a polyglutamine (polyQ) repeat tract whose abnormal expansion causes the neurodegenerative disease, Spinocerebellar Ataxia Type 3 (SCA3; also known as Machado-Joseph Disease). The ubiquitin chain cleavage properties of Atxn3 are enhanced when it is ubiquitinated at lysine (K) at position 117. K117-ubiqutinated Atxn3 cleaves poly-ubiquitin more rapidly in vitro compared to its unmodified counterpart and this residue is also important for Atxn3 roles in cell culture and in Drosophila melanogaster. How polyQ expansion causes SCA3 remains unclear. To gather insight into the biology of disease of SCA3, here we posited the question: is K117 important for toxicity caused by Atxn3? We generated transgenic Drosophila lines that express full-length, human, pathogenic Atxn3 with 80 polyQ with an intact or mutated K117. We found that K117 mutation mildly enhances the toxicity and aggregation of pathogenic Atxn3 in Drosophila. An additional transgenic line that expresses Atxn3 without any K residues confirms increased aggregation of pathogenic Atxn3 whose ubiquitination is perturbed. These findings suggest Atxn3 ubiquitination as a regulatory step of SCA3, in part by modulating its aggregation.

PDFDOI

02 /Specification & Classification

Click any tag to browse matching papers
Citations
6
FWCI
0.73
Field percentile
top 35%

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISLuo '23Ashraf '19Haas '20Yuan '26Watchon '24Robinson '21
78% semantic matchNeuroscience
Haiyang Luo, Sokol V. Todi, Henry Lauris Paulson+1 more·Frontiers in Molecular Neuroscience·Apr 14, 2023· 9 citations